Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer
Eur J Nucl Med Mol Imaging. 2023 Nov 29. doi: 10.1007/s00259-023-06540-6. Online ahead of print.NO ABSTRACTPMID:38017326 | DOI:10.1007/s00259-023-06540-6 (Source: Molecular Medicine)
Source: Molecular Medicine - November 28, 2023 Category: Molecular Biology Authors: Fernanda Miyuki Sasaki Aline Lopes Garcia Leal Paulo Jos é de Almeida Filho Felipe Alves Mourato Source Type: research
Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas
ConclusionsLID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - November 27, 2023 Category: Nuclear Medicine Source Type: research
Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas
CONCLUSIONS: LID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain.PMID:38008728 | DOI:10.1007/s00259-023-06523-7 (Source: Molecular Medicine)
Source: Molecular Medicine - November 26, 2023 Category: Molecular Biology Authors: Mika Tamura Kunihiro Nakada Haruna Iwanaga Naotoshi Fujita Katsuhiko Kato Source Type: research
Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas
CONCLUSIONS: LID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain.PMID:38008728 | DOI:10.1007/s00259-023-06523-7 (Source: Molecular Medicine)
Source: Molecular Medicine - November 26, 2023 Category: Molecular Biology Authors: Mika Tamura Kunihiro Nakada Haruna Iwanaga Naotoshi Fujita Katsuhiko Kato Source Type: research
Current practice in intermediate risk differentiated thyroid cancer - a review
Rev Endocr Metab Disord. 2023 Nov 23. doi: 10.1007/s11154-023-09852-y. Online ahead of print.ABSTRACTAlthough the overall prognosis for differentiated thyroid cancer (DTC) is excellent, a subset of patients will experience disease recurrence or may not respond to standard treatments. In recent years, DTC management has become more personalized in order to enhance treatment efficacy and avoid unnecessary interventions.In this context, major guidelines recommend post-surgery staging to assess the risk of disease persistence, recurrence, and mortality. Consequently, risk stratification becomes pivotal in determining the neces...
Source: ENDOCR REV - November 23, 2023 Category: Endocrinology Authors: Rosalia do Prado Padovani Fernanda Barbosa Duarte Camila Nascimento Source Type: research
Current practice in intermediate risk differentiated thyroid cancer - a review
Rev Endocr Metab Disord. 2023 Nov 23. doi: 10.1007/s11154-023-09852-y. Online ahead of print.ABSTRACTAlthough the overall prognosis for differentiated thyroid cancer (DTC) is excellent, a subset of patients will experience disease recurrence or may not respond to standard treatments. In recent years, DTC management has become more personalized in order to enhance treatment efficacy and avoid unnecessary interventions.In this context, major guidelines recommend post-surgery staging to assess the risk of disease persistence, recurrence, and mortality. Consequently, risk stratification becomes pivotal in determining the neces...
Source: ENDOCR REV - November 23, 2023 Category: Endocrinology Authors: Rosalia do Prado Padovani Fernanda Barbosa Duarte Camila Nascimento Source Type: research
Current practice in intermediate risk differentiated thyroid cancer - a review
Rev Endocr Metab Disord. 2023 Nov 23. doi: 10.1007/s11154-023-09852-y. Online ahead of print.ABSTRACTAlthough the overall prognosis for differentiated thyroid cancer (DTC) is excellent, a subset of patients will experience disease recurrence or may not respond to standard treatments. In recent years, DTC management has become more personalized in order to enhance treatment efficacy and avoid unnecessary interventions.In this context, major guidelines recommend post-surgery staging to assess the risk of disease persistence, recurrence, and mortality. Consequently, risk stratification becomes pivotal in determining the neces...
Source: ENDOCR REV - November 23, 2023 Category: Endocrinology Authors: Rosalia do Prado Padovani Fernanda Barbosa Duarte Camila Nascimento Source Type: research
Current practice in intermediate risk differentiated thyroid cancer – a review
AbstractAlthough the overall prognosis for differentiated thyroid cancer (DTC) is excellent, a subset of patients will experience disease recurrence or may not respond to standard treatments. In recent years, DTC management has become more personalized in order to enhance treatment efficacy and avoid unnecessary interventions.In this context, major guidelines recommend post-surgery staging to assess the risk of disease persistence, recurrence, and mortality. Consequently, risk stratification becomes pivotal in determining the necessity of postoperative adjuvant therapy, which may include radioiodine therapy (RIT), the degr...
Source: Reviews in Endocrine and Metabolic Disorders - November 23, 2023 Category: Endocrinology Source Type: research
Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study
CONCLUSION: Total cumulative doses of 100 mCi or less of RAI can be safely administered without concerns about second primary malignancy. However, the risk of second primary malignancy increases in a dose-dependent manner, and the risk-benefit needs to be considered for doses over 100 mCi of RAI therapy.PMID:37982105 | PMC:PMC10654320 | DOI:10.1007/s13139-023-00818-1 (Source: Molecular Medicine)
Source: Molecular Medicine - November 20, 2023 Category: Molecular Biology Authors: Chae Moon Hong Junik Son Min Kyung Hyun Jang Won Lee Jaetae Lee Source Type: research
A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases
The objective was to determine the maximum I-131 cumulative activity that could be safely administered without compromising efficacy. The secondary objective was to identify other prognostic factors affecting survival outcomes. Materials and methodsThis was a retrospective cohort study done at a tertiary-care institution comprising of data from January 1990-June 2020. 489 DTC patients having skeletal metastases with ≥12 months follow-up were included. Ninety-six percent of patients had thyroidectomy followed by radioiodine therapy for skeletal metastases. All patients were on oral suppressive levothyroxine tablets. Exter...
Source: PLoS One - November 14, 2023 Category: Biomedical Science Authors: Sivasankar Kanankulam Velliangiri Source Type: research
Wide Composite Resection of Sternal Metastasis & amp; Reconstruction Using Titanium Mesh Implant and Myocutaneous Flap in Differentiated Thyroid Carcinoma: Case Report of Two Cases
We report two cases of DTC with sternal metastases whom we successfully managed with surgical resection of the sternal lesion with reconstruction of the chest wall defect using titanium mesh implant and myocutaneous flap. (Source: Indian Journal of Otolaryngology and Head and Neck Surgery)
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - November 10, 2023 Category: ENT & OMF Source Type: research
Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)
Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2185-7885. Online ahead of print.ABSTRACTThis version of the guideline for radioiodine therapy of benign thyroid disorders is an update of the version, which was published by the German Society of Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizin, DGN) in co-ordination with the German Society of Endocrinology (Deutsche Gesellschaft für Endokrinologie, DGE, Sektion Schilddrüse) and the German Society of General- and Visceral-Surgery (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie, DGAV) in 2015. This guideline was harmonized with the recommendations of the...
Source: Nuklearmedizin - October 23, 2023 Category: Radiology Authors: M Dietlein F Gr ünwald M Schmidt M C Kreissl M Luster Deutsche Gesellschaft f ür Allgemein- und Viszeralchirurgie e. V. (DGAV) Chirurgische Arbeitsgemeinschaft Endokrinologie (CAEK) der DGAV Deutsche Gesellschaft f ür Chirurgie e. V. (DGCH) Deuts Source Type: research
Commentary on the latest DGN procedure guidelines for radioiodine therapy for benign thyroid diseases
Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2185-8082. Online ahead of print.ABSTRACTDie aktuelle DGN-Handlungsempfehlung behandelt das Thema der Entwicklung der TRAK-Spiegel nach der Radiojodtherapie der Immunhyperthyreose erstmals im Vergleich zu den vorangehenden Versionen. Diese neuen Hinweise sollten differenziert eingeordnet und anschließend dem Patienten z.B. in den Aufklärungsunterlagen geeignet zugänglich gemacht werden. Bei der Verwendung fertiger kommerzieller Aufklärungsbögen, herausgegeben von einigen medizinisch orientierten Verlagsgesellschaften, ist auf deren Aktualität zu achten, ggf. sind die noch n...
Source: Nuklearmedizin - October 23, 2023 Category: Radiology Authors: Markus Dietlein Alexander Drzezga Matthias Schmidt Source Type: research
Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)
Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2185-7885. Online ahead of print.ABSTRACTThis version of the guideline for radioiodine therapy of benign thyroid disorders is an update of the version, which was published by the German Society of Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizin, DGN) in co-ordination with the German Society of Endocrinology (Deutsche Gesellschaft für Endokrinologie, DGE, Sektion Schilddrüse) and the German Society of General- and Visceral-Surgery (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie, DGAV) in 2015. This guideline was harmonized with the recommendations of the...
Source: Nuklearmedizin - October 23, 2023 Category: Radiology Authors: M Dietlein F Gr ünwald M Schmidt M C Kreissl M Luster Deutsche Gesellschaft f ür Allgemein- und Viszeralchirurgie e. V. (DGAV) Chirurgische Arbeitsgemeinschaft Endokrinologie (CAEK) der DGAV Deutsche Gesellschaft f ür Chirurgie e. V. (DGCH) Deuts Source Type: research
Commentary on the latest DGN procedure guidelines for radioiodine therapy for benign thyroid diseases
Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2185-8082. Online ahead of print.ABSTRACTDie aktuelle DGN-Handlungsempfehlung behandelt das Thema der Entwicklung der TRAK-Spiegel nach der Radiojodtherapie der Immunhyperthyreose erstmals im Vergleich zu den vorangehenden Versionen. Diese neuen Hinweise sollten differenziert eingeordnet und anschließend dem Patienten z.B. in den Aufklärungsunterlagen geeignet zugänglich gemacht werden. Bei der Verwendung fertiger kommerzieller Aufklärungsbögen, herausgegeben von einigen medizinisch orientierten Verlagsgesellschaften, ist auf deren Aktualität zu achten, ggf. sind die noch n...
Source: Nuklearmedizin - October 23, 2023 Category: Radiology Authors: Markus Dietlein Alexander Drzezga Matthias Schmidt Source Type: research
